good come back. But can you beat this....ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
"""ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis """- when the New Drug App gets filed later THIS YEAR it will probably break $30-$40 range.
I let the shorts and newbies do the heavy lifting...but smart shorts will always make money. Don't underestimate them as a group they are smart and monitor the stock much closer than longs. They are in and out ...although they tend to be happy with frequent small gains in a stock like ACAD and may play both sides.... Cover and go long/swing trade or sell and short. We, as longs, love to think of them as dumb...but I know better.
Dude..you don't need a stock chart to tell you if its Red or White, it opened Higher (Open: 26.76) than it is now so its RED.
First of all with few exceptions every biotech that releases a drug will say the price will be "competitive". You can ignore that till the drug is released and see what the price really is and how the drug insurance companies who pay for the drug deal with it. I'll let you figure it out, but consider if I am wrong, why is the price of this stock $7+? They have a "new drug " approved...they have a good partner...so why is the stock $7. If you think this drug will be a slam dunk...you are a fool soon to be departed from your money. Now you may continue your name calling argument.
In 30 years I never had one patient tell me their injection site was severely painful or moderately even for 30 seconds post injection. They seem to accept it or it just wasn't bad enough to complain about. As a matter of fact, the biggest complaint from insulin users was the blood sugar testing in their fingers. And all Diabetics have to do that no matter if on insulin or not.
Who pays for recommended drugs? Drug insurance companies do and they will block the use of new drugs as they usually do with Protocols and High Co-Pays that no patient wants to pay. Especially with so many other generic products available with low Co-Pays and tiny needle insulin Pens that patients love. Also, some doc's have been recommending early start insulin for the T2's for many years...its not a new theory. Some of you think its "new" thinking", its not. I heard that talk over 15 years ago. So having an inhaled insulin will not see much of a bump on early insulin use. Sorry guys, this drug will be used in only a few "special cases " ( recurrent MRSA skin infections, severe bleeding disorders, poor vision, maybe documented Needle Phobia, etc ) . Maybe 1% of the Diabetic T1/T2's. The MNKD story is in the technology for other drugs...Not inhaled insulin...by the way - this has already failed the stockholders with such a poor showing-very low price targets etc, . Now if you want, take a little more Kool-Aid.
" Afrezza could be used as a first-line insulin for almost 8% of type 2 patients "- 8% first line NO WAY...yeah and your seat cushion could be a flotation device....Dude Afrezza will be lucky to be used for 1% of the Diabetics t1/t2.